DIM (diindolylmethane) and cervical health

What 3 graded rows on dim (diindolylmethane) agree on for cervical health, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the DIM (diindolylmethane) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the DIM (diindolylmethane) page, with its PubMed record.

Supplement

DIM (diindolylmethane) Choose another

3 rows · 693 people

Mostly no difference: 2 of 3 rows, and most of the people. 1 found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

Trial sizeWhen publishedGrade

The best-graded row, grade C, is a randomized trial of 551 people (2012) and found no difference.

The 2 rows that found no difference were larger: a median of 308 people, against 78 people for the row that found an improvement.

The row that found an improvement is newer (2015) than the 2 rows that found no difference (2010 to 2012).

The best grade is C among the rows that found no difference, and D among the row that found an improvement.

1 improved · 2 no difference

Grade CCervical cytology, CIN2+ and HPV in low-grade cervical abnormalities · No difference
RCT · n 551 · 2012 · Women with newly found low-grade cervical cytological abnormalities (UK)
150 mg DIM once daily · 6 months
CIN2 or worse in 9% on DIM vs 12% on placebo (RR 0.7, 95% CI 0.4–1.2); CIN3 or worse RR 0.9 (0.4–2.0). HPV persisted in 69% on DIM vs 61% on placebo (RR 1.1). The authors concluded DIM is unlikely to affect cytology or HPV, with uncertainty about CIN2+.
Row on the DIM (diindolylmethane) page · PubMed 22075942 (opens PubMed)
Grade DCervical lesions (CIN2–3) before planned excision · No difference
Pilot RCT · n 64 · 2010 · Women with biopsy-proven CIN2 or CIN3 (USA)
About 2 mg/kg/day · 12 weeks
No statistically significant difference between DIM and placebo in any outcome; 2 people on DIM reported nausea.
Row on the DIM (diindolylmethane) page · PubMed 19939441 (opens PubMed)
Grade DRegression of CIN I–II with DIM vaginal suppositories · Improved
RCT · n 78 · 2015 · Women of reproductive age with CIN I–II (Russia)
100 or 200 mg/day intravaginally · 90–180 days
Complete regression in 100% (200 mg), 90.5% (100 mg) and 61.1% (placebo). Adverse events were more frequent on DIM (40–42% vs 22%), none serious.
Row on the DIM (diindolylmethane) page · PubMed 26693258 (opens PubMed)